| |
Controls (N = 8)
|
Diabetics (N = 6)
|
|---|
|
Age, years (range)
|
44 (28 – 59)
|
57 (42 – 71)*
|
|
BMI, kg/m2
|
25.7 ± 3.4
|
30.7 ± 9.4
|
|
Duration of diabetes (year)
|
-
|
7.7 ± 5
|
|
Fasting blood glucose (mmol/l)
|
4.9 ± 0.4
|
8.5 ± 1.5*
|
|
HbA1c (%)
|
5.4 ± 0.2
|
6.8 ± 0.8*
|
|
Total cholesterol (mmol/l)
|
5.1 ± 0.8
|
3.7 ± 0.3*
|
|
LDL cholesterol (mmol/l)
|
3.1 ± 0.7
|
1.8 ± 0.3*
|
|
HDL cholesterol (mmol/l)
|
1.3 ± 0.5
|
1.2 ± 0.4
|
|
Triglycerides (mmol/l)
|
1.4 ± 0.8
|
2.5 ± 2.9
|
|
Creatinine (μmol/l)
|
83 ± 12
|
69 ± 10
|
|
Urea (mmol/l)
|
5.5 ± 0.8
|
5.0 ± 0.9
|
|
Oral antidiabetic therapy (nr of patients)
| | |
|
Metformin
| |
4
|
|
Glimepiride
| |
3
|
|
Exenatide
| |
1
|
|
Gliclazide
| |
1
|
|
Liraglutide
| |
1
|
|
Pioglitazone
| |
1
|
- BMI: body mass index; LDL: low-density lipoprotein; HDL: high-density lipoprotein. Data are represented as mean ± SD unless indicated otherwise; Mann–Whitney U test, * p < 0.05.
